Intercept Pharmaceuticals Archives - ONE-TWENTY TWO: Trading Financial Markets

Intercept Pharmaceuticals Loses More Momentum As Morgan Stanley Weighs

August 13, 2015 by Dr. Duru

Morgan Stanley (MS) initiated coverage on Intercept Pharmaceuticals, Inc. (ICPT) with an underweight rating. The negativity weighed on the stock for a 7.9% loss that sent the stock below critical support at its 200-day moving average (DMA). Source: FreeStockCharts.com Morgan was VERY emphatic about its “out of consensus” call on ICPT. As reported by Investors.com: … Read more

T2108 Update (March 23, 2015) – Countdown (Again) to Overbought Market Conditions

March 24, 2015 by Dr. Duru

(T2108 measures the percentage of stocks trading above their respective 40-day moving averages [DMAs]. It helps to identify extremes in market sentiment that are likely to reverse. To learn more about it, see my T2108 Resource Page. You can follow real-time T2108 commentary on twitter using the #T2108 hashtag. T2108-related trades and other trades are … Read more

T2108 Update (February 20, 2015) – All-Time Highs Increase Technical Tensions

February 22, 2015 by Dr. Duru

Intercept Pharmaceuticals Raises Much Needed Cash As Shorts Accelerate Their Bets

February 4, 2015February 4, 2015 by Dr. Duru

After the market closed for trading on January 29, 2015, Intercept Pharmaceuticals (ICPT) released exciting news: ICPT’s “…investigational product obeticholic acid (OCA) has received “breakthrough therapy designation” from the U.S. Food and Drug Administration (FDA) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. This indication constitutes a population of patients with … Read more

T2108 Update (August 25, 2014) – S&P 500 2K Edition

August 25, 2014August 25, 2014 by Dr. Duru

A Technician’s Wary Eye On Intercept Pharmaceuticals, Inc.

August 12, 2014August 12, 2014 by Dr. Duru

Intercept Pharmaceuticals, Inc. (ICPT) may indeed have the $5B blockbluster liver drug that RBC Capital Markets claimed in hiking its price target on the stock from $425 to $500. Gilead (GILD) may indeed buy out the company. Other analysts like Leerink Partners who raised its price target from $270 to $445, and Deutsche Bank who … Read more

T2108 Update (January 10, 2014) – Just A Hair Away from Overbought

January 12, 2014January 13, 2014 by Dr. Duru